PHARMACOLOGICAL ACTIONS OF "8204" ON CARDIOVASCULAR SYSTEM AND BRONCHIAL SMOOTH MUSCLE

8204 (1- (2,3,4-trimethoxybenzyl)-4-(α-trimethysilyloxy-2-(4-amino-3′, 5′-dichlorophenyl) ethyl) piperazine dihydroehloride) was synthesized by Henan Institute of Pharmaceutical Industrial Research. "8204" had been shown to increase coronary flow in isolated rabbit heart. In anesthetized open-chest dogs, intravenous injection of "8204" (4 mg/kg) enhanced coronary venous flow, lowered myocardial O₂ consumption and slowed heart rate."8204" was shown to increase the tolerance of mice to hypoxia and prevent rats from pituitrin induced change of ECG. "8204" exhibited relaxing effect on guineapig tracheal smooth muscle made to contract by acetylcholine and histamine. It increased the perfusion rate of isolated lung preparation of guinea-pig from 5.7±2.0 to 16.3±5.8 ml/min (p<0.001).Intraperitioneal injection of "8204" 2 mg/kg showed prominent protective effect against bronchial asthma induced by inhalation of histamine in conscious guineapig.In rats given "8204" 20 mg/kg or 40 mg/kg per day orally for three months, no obvious pathological change in various tissue was found.It appears that "8204" probably have helpful effects in the treatment of coronary heart disease, and may be an effective antiasthmatic agent.